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S U M M A R Y
Objective: To determine the effectiveness of empiric antibiotic regimens covering atypical pathogens
with respect to detailed clinical and economic outcomes in community-acquired pneumonia (CAP).
Methods: A population-based, multicenter, retrospective cohort study was conducted from June 2010 to
May 2011. Patients with a diagnosis of CAP were enrolled and categorized into two groups according to
the initial antibiotic strategy used – covering or not covering atypical pathogens. Regression analysis was
performed to assess their clinical outcomes (all-cause mortality, clinical improvement rate after 72 h of
antimicrobial therapy, and clinical cure rate) and economic outcomes (length of stay, hospitalization
costs, and antibiotic expenditure).
Results: A total of 827 patients met the criteria for CAP; 561 (67.8%) received antibiotics with atypical
pathogen coverage (APC group), while 266 (32.2%) did not (non-APC group). Regression analysis revealed
that the all-cause mortality was much lower in the APC group than in the non-APC group (0.9% vs. 4.9%,
respectively), with an odds ratio (OR) of 0.18 (95% conﬁdence interval (CI) 0.06–0.49). Clinical
improvement at 72 h (87.7% vs. 85.0%, p = 0.274) and the clinical cure rate (91.1% vs. 88.3%, p = 0.213)
were more favorable in the APC group, but with no signiﬁcant difference compared to the non-APC
group. Moreover, the APC group had a shorter mean length of stay (APC 10.2 days vs. non-APC 11.6 days,
p < 0.001). In addition, the mean total hospitalization costs for the APC group were markedly lower
compared with the non-APC group (US$ 1172.7 vs. US$ 1510.7; p < 0.001).
Conclusion: Antimicrobial treatment covering atypical pathogens for hospitalized CAP patients is
associated with reduced mortality and economic burden.
 2015 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Community-acquired pneumonia (CAP) represents a common
and potentially life-threatening illness that continues to be a major
medical problem. The clinical and socioeconomic impact of CAP is
better appreciated by the growing prevalence of the disease, owing
to both its age-dependency,1 and the current upward trend in life
expectancy. Data from the USA have shown the incidence rate to be
as high as 10.6 per 1000 person-years,2with 19.6% of these patients
requiring hospitalization (1.1 million annual hospitalizations)3 and
19.8% of hospitalized patients requiring admission to the intensive
care unit (ICU).4 Within Europe, the overall annual incidence of
CAP in adults ranges between 1.1 and 1.2 per 1000 person-years
and between 1.5 and 1.7 per 1000 population, and increases with
age (14 per 1000 person-years in adults aged 65 years).5
However, large-scale epidemiological investigations of CAP in
China are still lacking. In one study, limited crude data showed that
6.1% of febrile outpatients were diagnosed with CAP.6 Moreover,
CAP has been described as a public health issue of substantial
magnitude that exerts a heavy toll on the patient, their family, and
society. The economic burden associated with CAP remains
substantial at more than US$ 17 billion annually in the USA,7
and US$ 556.50 for median total hospital costs (mean US$ 705.60)
in a rural region of China.8
In recent years, the spectrum of causative pathogens of CAP has
shifted following the widespread indiscriminate use of antibiotics,
aging of the general population, and improvements in the accuracy
of clinical diagnosis. Studies have shown that the rate of
Streptococcus pneumoniae has recently declined in CAP; however,
the rate of infection with atypical pathogens like Chlamydia
pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila
has risen. The proportion of atypical pneumonia in hospitalized
CAP patients has been reported to be 8–44%.9 In Western society,
M. pneumoniae, C. pneumoniae, and L. pneumophila have been
ranked second, fourth, and ﬁfth most common causative patho-
gens of CAP, respectively.10 A previous study done by our group,
involving 593 adult patients with CAP, revealed M. pneumoniae to
be the most common pathogen (38.9%), followed by S. pneumoniae
(32.6%).11
Available evidence to support the use of broad antibiotic
regimens containing atypical pathogen coverage is insufﬁcient,
while limiting coverage is bound to reduce toxicity, resistance,
and costs. A meta-analysis encompassing 28 trials and 5939 ran-
domized patients comparing empiric antibiotic regimens with
atypical coverage (quinolones, macrolides, tetracyclines, chlor-
amphenicol, streptogramins, or ketolides) against regimens with
typical coverage only, indicated no beneﬁt in terms of survival or
clinical efﬁcacy for atypical coverage in hospitalized patients
with CAP.12 The aim of the present study was to investigate the
clinical outcomes and economic burden of the use of antibiotic
coverage for atypical pathogens or not in 827 patients with CAP
hospitalized in municipal and community hospitals in China;
this was a population-based, multicenter, retrospective cohort
study.
2. Patients and methods
2.1. Subjects
CAP data from a period of 12 months (June 1, 2010 to May 31,
2011), collected at 10 participating institutions (four municipal
and six community hospitals), were analyzed retrospectively. All
patients enrolled had clinical features and radiological ﬁndings
compatible with the diagnostic criteria set out in the 2006 CAP
Diagnosis and Treatment Guidelines of the Respiratory Society of
the Chinese Medical Association.13 A subject was included if he orshe had presented patchy inﬁltrates or consolidation shown on a
chest X-ray, along with at least three of the following signs and
symptoms: (1) recent cough, sputum, aggravated respiratory
symptoms, or acute changes in the quality of sputum (<10
epithelial cells and >25 leukocytes per low-power ﬁeld on
microscopy), with or without chest pain; (2) fever (>38 8C) or
hypothermia (<36 8C) within the preceding 24 h; (3) moist rales;
(4) leukocytosis (white blood cell count >10  109/l, or 15% bands).
This study ruled out mimic pneumonias, referring to deﬁned
bronchopulmonary diseases that might easily be confused with the
diagnosis of CAP, such as tuberculosis, healthcare-associated
pneumonia, aspiration pneumonia, lung cancer, non-infectious
interstitial lung disease, pulmonary edema, atelectasis, pulmonary
embolism, pulmonary eosinophilic granulocyte inﬁltrating dis-
ease, and pulmonary vasculitis. Patients who had taken antibiotic
therapy within the 72 h preceding hospitalization were excluded.
Patients with HIV or who had been hospitalized within 14 days
prior to study enrollment were also excluded. Patients who had
received initial empirical antibiotic regimens with quinolones,
macrolides, tetracyclines, chloramphenicol, streptogramins, or
ketolides for more than 48 h within 72 h before and after
admission were deﬁned as having received atypical pathogen
coverage (APC). This study was approved by the local ethics
committees and institutional review boards of the study hospitals.
2.2. Baseline and outcome measurements
2.2.1. Baseline data
Case report forms (CRFs) were used to collect patient
demographic data, medical history, and concurrent diseases, and
to check their antibiotic regimens, including details of the type,
dosage, routes of administration, and date of start and withdrawal
during hospitalization. These latter data were used to determine
whether the antibiotics covered atypical pathogens or not, to
evaluate the effectiveness of antibiotic therapy (whether switched
from intravenous use to oral), and to exclude patients receiving
antibiotics with APC beyond the time limitation (more than 48 h
within 72 h before and after admission). As well as considering
routine examinations, the detection of biomarkers was particularly
re-evaluated to identify the clinical response after 72 h of
intravenous treatment. The Pneumonia Severity Index (PSI) was
used to evaluate the severity of pneumonia. This index is scored
according to the patient’s general condition, medical history,
comorbidities, physical examination ﬁndings, and laboratory and
radiographic ﬁndings. It provides a means of stratifying groups of
patients according to their risk of mortality and features. A score of
>90 represents moderate to severe pneumonia.
2.2.2. Outcome measurements
The primary endpoint was all-cause in-hospital mortality. The
secondary endpoints included the clinical improvement rate after
72 h of intravenous treatment, clinical cure rate, length of stay
(LOS), total cost of hospitalization, and direct cost of antibiotics.
2.2.3. Clinical outcome measurements
Clinical improvement was considered present if the patient
experienced defervescence and an improvement in respiratory
symptoms, had a normal white blood cell count, and showed an
improvement on chest X-ray.
Clinical cure was deﬁned as discharge without any sign or
symptom of pneumonia, as well as no further need for antibiotic
treatment.
Treatment was classiﬁed as ‘failure’ if any of the following
situations occurred: death, need to stay in hospital for more than
28 days, clinical deterioration as evidenced by an increase in
temperature after initial improvement or requiring mechanical
Table 1
Demographic and baseline characteristics of patients with community-acquired
pneumonia (N = 827)a
Characteristics APC, n (%) Non-APC, n (%) p-Value
Gender, female 245 (43.7) 118 (44.7) 0.852
Age, years, mean (SD) 61.9 (20.3) 60.3 (22.6) 0.304
65 years 276 (49.2) 146 (54.9) 0.126
Smoker 393 (70.1) 199 (74.8) 0.156
Underlying bronchopulmonary
disease
47 (8.3) 21 (7.8) 0.294
Cough 479 (85.4) 212 (79.7) 0.114
Chest X-ray/CT ﬁndings
Inﬁltrate 651 (100.0) 266 (100.0) -
Pleural effusion 99 (17.6) 54 (20.3) 0.359
PSI score, mean (SD) 25.3 (77.9) 31.7 (76.9) 0.854
PSI > 90 194 (34.6) 86 (32.3) 0.530
Hospital type
Community hospital 224 (39.9) 121 (45.4) 0.130
Municipal hospital 337 (60.1) 145 (54.5) 0.130
APC, atypical pathogen coverage; SD, standard deviation; CT, computed tomogra-
phy; PSI, Pneumonia Severity Index; CHD, Chronic Heart Diseases.
a Data are presented as the number (%) unless speciﬁed otherwise. The mortality
of patients with CHD or non-CHD in the APC and non-APC groups had no
signiﬁcance.
X. Ye et al. / International Journal of Infectious Diseases 40 (2015) 102–107104ventilation, switch from oral to intravenous antibiotics, or
readmission for pulmonary re-infection after discharge.
2.2.4. Economic outcome measurements
The total cost of CAP hospitalization included costs for
laboratory testing, chest X-rays, medications, and nursing care
during the hospitalization, while the direct costs of the antibiotic
regimens covered only what was paid for the medicine, but not
additional costs for diagnosis or care. For the ease of cost
comparison with other international studies, Chinese Yuan were
converted into US dollars (US$) as the currency unit (1 US dollar is
equivalent to 6.23 Yuan.)
2.3. Statistical analysis
Results were presented as the absolute number with the
percentage, or as the mean  standard deviation (SD). Binary
variables were analyzed using Fisher’s exact test, and continuous
variables were compared using the Mann–Whitney U-test. Odd ratios
(ORs) and 95% conﬁdence intervals (CIs) were reported for logistic
regression analysis. A two-tailed p-value of <0.05 was considered
signiﬁcant. Linear regression models adjusting for the severity of
baseline diseases – speciﬁcally, simple linear regression for economic
outcomes and logistic regression for clinical outcomes – were
performed. All CIs for differences in proportions were calculated
using the normal approximation to the binomial distribution. The
statistical analysis was performed using SPSS v. 18.0 software
package (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Demographic and baseline characteristics of the study
participants
Among 1537 patients who met the CAP diagnosis, a total of
827 patients fulﬁlled the inclusion criteria. These patients were
divided into two groups based on the antibiotics administered: the
APC group (561 patients, 67.8%) and the non-APC group
(266 patients, 32.2%). The remaining 710 patients were excluded
for the following reasons: incomplete or no radiographic dataFigure 1. Flow chart of the study selection process (abbreviations: CAP, community-acqu(31 patients), antibiotic treatments prior to hospitalization
(484 patients), and mimic pneumonia (195 patients). Figure 1
depicts the study ﬂowchart.
The baseline characteristics of the patients are shown in
Table 1. There was no difference between the APC and non-APC
groups with regard to age (APC group, 61.9  20.3 years vs. non-APC
group, 60.3  22.6 years; p = 0.304) or gender (APC group, 43.7%
female vs. non-APC group, 44.4% female; p = 0.852) at baseline. In
addition, the percentages with underlying bronchopulmonary dis-
eases (8.3% vs. 7.8%; p = 0.294), cough (85.4% vs. 79.7%; p = 0.114),
inﬁltrates on X-ray examination (100.0% vs. 100.0%), and pleural
effusion (17.6% vs. 20.3%; p = 0.359) were comparable in the two
groups, as was the PSI score (77.9  25.3 vs. 76.9  31.7; p = 0.854).
Approximately one third of the patients in both groups had a PSI >90,
with no statistically signiﬁcant difference. Moreover, no great
difference was found in antibiotic regimens for the different hospital
types. Overall, 39.9% of patients in the APC group had receivedired pneumonia; APC, atypical pathogen coverage; PSI, pneumonia severity index).
Figure 2. Subgroup analysis of the effect of atypical pathogen coverage (APC) on all-cause mortality during hospitalization. Note: Insurance refers to mean insurance
coverage; 15.0% (84/561) of the APC patients and 19.5% (52/266) of the non-APC patients had insurance coverage, accounting for 10.2% and 6.3% of all community-acquired
pneumonia patients.
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while in the non-APC group, 45.4% were treated in a community
hospital and 54.5% in a municipal hospital.
3.2. Types of antibiotic in the atypical coverage arm
Levoﬂoxacin (49.4%), azithromycin (30.3%), and moxiﬂoxacin
(16.9%) were the most commonly prescribed antibiotics covering
atypical pathogens.
3.3. Clinical outcomes
The all-cause mortality rate of the APC group (0.9%) was
signiﬁcantly lower than that of the non-APC group (4.9%; 95% CI
2.6–8.2; p = 0.002). After adjustment for age, gender, underlying
bronchopulmonary diseases, PSI score, bilateral pulmonary
inﬁltrates on X-ray, and hospital type, multiple logistic regression
analysis showed the OR for assessing the antibiotic regimensTable 3
Analysis of the economic outcomes of antibiotic therapya
Response APC
(n = 561)
No
(n =
LOS, days 10.2 (4.3) 11
Hospital expenditure, US$ 1172.7 (774.5) 15
Antibiotic expenditure, US$ 425.9 (339.8) 50
APC, atypical pathogen coverage; CI, conﬁdence interval; LOS, length of stay.
a Data are presented as the mean (standard deviation).
b By linear regression models controlling for baseline disease severity.
Table 2
Clinical outcomes of patients with community-acquired pneumonia (N = 827)a
Response APC, % (n) No
All-cause mortality 0.9 (5) 4
Clinical improvement at 72 h 87.7 (492) 85
Clinical cure 91.1 (511) 88
APC, atypical pathogen coverage; OR, odds ratio; CI, conﬁdence interval.
a By multivariate logistic regression, controlling for baseline disease severity.covering atypical pathogens within 72 h before and after admis-
sion to be 0.18 (95% CI 0.06–0.49; p = 0.001). When mortality was
stratiﬁed by patient characteristics, the OR was 0.10 (95% CI
0.02– 0.47) for patients with no adjunctive corticosteroid, 0.10
(95% CI 0.02–0.49) for patients treated in municipal hospitals
(Figure 2), and 0.11 (95% CI 0.03–0.40) for patients without
underlying bronchopulmonary diseases. Detailed clinical out-
comes are shown in Table 2. Clinical improvement at 72 h and
clinical cure were observed in 87.7% (non-APC 85.0%; OR 1.26, 95%
CI 0.83–1.92; p > 0.05) and 91.1% (non-APC 88.3%; OR 1.35, 95% CI
0.84–2.17; p > 0.05) of the patients in the APC group, respectively,
which showed an insigniﬁcant advantage over non-APC.
3.4. Economic burden of disease
The cost of treatment for CAP was compared between the APC
group and the non-APC group (Table 3). The APC group had a
hospital stay of 1.5  0.4 days less than the non-APC group (95% CIn-APC
 266)
Mean difference
(95% CI)
p-Valueb
.6 (5.2) 1.5 (0.8–2.2) <0.01
10.7 (1060.9) 338.0 (209–466.1) <0.01
2.9 (361.9) 77.0 (26.3–127.7) <0.01
n-APC, % (n) p-Valuea OR (95% CI)
.9 (13) 0.001 0.18 (0.06–0.49)
.0 (226) 0.274 1.26 (0.84–2.20)
.3 (235) 0.213 1.35 (0.84–2.17)
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338.0  65.3 less; 95% CI 209.0–466.1; p < 0.01), and lower direct
antibiotic cost (US$ 77.0  25.8 less; 95% CI 26.3–127.7; p < 0.01). In
terms of the antibiotic deﬁned daily dosage (DDD), the DDD of the
APC group (19.2  11.6) was higher than that of the non-APC group
(18.3  10.8), although the difference was not statistically signiﬁcant
(p = 0.28).
4. Discussion
CAP is categorized into ‘typical’ and ‘atypical’ pneumonia
depending on the type of causative agent, and this leads to the use
of different therapeutic strategies. With the change in pathogen
spectrum mentioned above, this situation might also be changing.
However, there are no up-to-date data on the beneﬁt of empirical
antimicrobial treatment covering atypical pathogens in CAP.
Additionally, due to the absence of CAP-related epidemiological
data across the country, difﬁculty in obtaining qualiﬁed specimens
for culture and in prescribing broad-spectrum antibiotics before a
deﬁned diagnosis, and also limitations in diagnostic techniques, it
is difﬁcult to make a clear assessment of the clinical and economic
impact of CAP in China.
It has been concluded that the mortality of CAP patients with
disease caused by atypical pathogens alone or as a part of multiple
infections is signiﬁcantly higher, especially in patients with
Legionella pneumonia, compared to patients with disease caused
by ordinary bacterial infections.14 Thus there appears to be an
urgent need to implement APC to reduce the mortality. The current
study analyzed 827 hospitalized CAP patients, of whom approxi-
mately two-thirds received antibiotics for atypical pneumonia,
which is close to the percentage reported from Europe (74%), but
lower than that of the USA (91%).15 Although quinolone mono-
therapy has shown no survival beneﬁt or clinical efﬁcacy with
empirical APC for CAP patients compared to beta-lactam therapy,16
ﬂuoroquinolones were still the most commonly used antibiotics in
our APC group, among which levoﬂoxacin and moxiﬂoxacin
accounted for approximately half and one-ﬁfth of the APC patients,
respectively. This might be explained by the current situation in
China, where atypical pathogens (including C. pneumoniae) have
generally shown high resistance to macrolides but not to
ﬂuoroquinolones.17,18
Data from the Community-Acquired Pneumonia Organization
(CAPO) International Cohort Study disclosed that the mortality of
CAP in three continental regions (USA/Canada, Europe, and Latin
America) ranged from 7.2% to 13.3%,19 which is far higher than the
mortality found in the present study (2.2%, 18/827). Several
confounding variables might be responsible, such as the PSI score
and the Chinese culture in medical care. Kim et al. found that the
subgroup 30-day mortality increased signiﬁcantly with the
increase in PSI (p < 0.001), with a linear association.20 Likewise,
the low mortality among our patients might also be the result of
their relatively low PSI risk class. Moreover, as a consequence of
the inconsistent Chinese medical reimbursement schemes, in
which the cost of hospitalization treatment is covered to a greater
extent than outpatient treatment, approximately a third of our
patients were found to have had a PSI of <90 on admission,
although such patients are often recommended for outpatient
treatment according to the Infectious Diseases Society of America/
American Thoracic Society IDSA/ATS guidelines.21 In addition,
more than half of the patients were treated in community
hospitals, in which patients with less serious conditions were
found in a larger proportion than in the municipal hospitals,
consequently showing less mortality, although there was no
signiﬁcant difference in mortality between the two types of
hospital. Unfortunately, we only evaluated the outcomes (dead or
alive) of patients during their hospital stay, but regardless of thefollow-up of the discharged patients who died from CAP, there is
the possibility that mortality was underestimated. However,
patients who are ‘cured’ or who have ‘improved remarkably’ are
always allowed to leave the hospital in Chinese traditional culture.
CAP exerts a heavy ﬁnancial burden worldwide, from US$
12–31 million total healthcare expenses in central Europe, with
hospitalization representing over 90% of the direct costs of
treatment,22 to US$ 10.6 billion in the USA for an annual
950 000 new cases, of which 20% represents productivity costs.23
Dambrava et al. studied 780 hospitalized CAP patients retrospec-
tively and found that coverage for atypical pneumonia pathogens
as per the ATS/IDSA guidelines shortened the hospital stay by
2.8 days (APC 7.6 days vs. non-APC 10.4 days).24 Similar ﬁndings
were reported in a global multicenter study on 3233 cases of CAP.25
There is no doubt that this reduction in LOS will be of great
economic beneﬁt. A cohort study by the Pneumonia Patient
Outcomes Research Team showed that a reduced duration of
hospitalization by even 1 day could signiﬁcantly save healthcare
costs and improve the utilization of medical resources.26
Several limitations should be taken into account when
generalizing the study ﬁndings for clinical practice. Firstly, as a
retrospective cohort study, certain biases cannot be avoided. These
were minimized by designing a multicenter study covering both
community and municipal hospitals. To our knowledge, this is the
largest study in terms of sample size to evaluate the clinical and
economic beneﬁts of antibiotics covering atypical pathogens for
CAP in China. Secondly, as a result of a lack of clinician awareness
with regard to the need to collect specimens for inspection,
difﬁculties in obtaining sterile samples for culture, technical
limitations in performing the microbiological tests, and in turn,
frequent conjectural antibiotic treatment before diagnosis, only a
small proportion of the patients had data on the causative agent; it
was thus not possible to provide direct etiological evidence of the
beneﬁt of treatment covering atypical pneumonia. Thirdly, the
data only reﬂect the mortality during hospitalization, which makes
it difﬁcult to compare the results with mortality rates observed in
studies of CAP patients followed for a longer time.
In conclusion, the results of this study provide critical
information for public health analysis and recommendations for
the improved care of CAP patients in China. It is suggested that the
prescription of antibiotics with coverage of atypical pneumonia
pathogens for CAP patients could improve the patient mortality
rate and reduce medical costs.
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